-
Phase III clinical was smashed!
Time of Update: 2022-08-15
In fact, it is not uncommon for multinational pharmaceutical companies to fail in the R&D of new drugs, including Roche and Sanofi The failure of Merck's project R&D has attracted the attention of the industry.
-
The world's top 10 generic drug giants, who is carrying the load, and who is "running naked"?
Time of Update: 2022-08-15
It is worth noting that although Teva and Novartis' Sandoz are ranked first or second in the world, they are also the only two companies in the TOP10 list whose sales performance of generic drugs has declined, with a negative growth of about 3% .
-
What is the current performance of the API companies that have transformed into "APIs + CDMO"?
Time of Update: 2022-08-15
. Regarding the reasons for the growth in performance, Hepalink believes that thanks to the company's continuous development of enoxaparin sodium preparations in various regions of the world and the steady growth of API business orders, the company's heparin industry chain business revenue has achieved rapid growth; at the same time, based on the orders in hand.
-
In order to expand their business, a group of pharmaceutical companies are accelerating the establishment and acquisition of subsidiaries
Time of Update: 2022-08-15
On May 12, Saisheng Pharmaceutical issued an announcement stating that according to the company's strategic planning and business development needs, it held the 17th meeting of the fourth board of directors on May 12, 2022, and reviewed and approved the "Regulations on the Establishment of Foreign Investments".
-
Question is high!
Time of Update: 2022-08-15
If you don’t catch up with the live broadcast, move your small bench to find the answer in the review~ Then, Zhuang Kai takes us to the second perspective of sludge treatment and disposal - ""No Urban Solid Waste Treatment and Disposal under the Background of “Waste City” Construction: Experience in Deep Water How does the "gas, liquid and slag" technical route of Bei Pai deal with these problems?
-
Under the tide of resignation of pharmaceutical companies, executives "run away in groups" frequently!
Time of Update: 2022-08-15
On May 9, Ding Changtian applied for his resignation as a director of the company, a member of the Strategic Development and Investment Committee of the Board of Directors, and a member of the Remuneration and Assessment Committee of the Board of Directors for personal reasons; on March 11, Heavy Pharmaceutical Holdings received the resignation report of Chairman Liu Shaoyun; also in March, the company announced the resignation of Deputy General Manager and Chief Financial Officer Zhang Hong .
-
China Pharmaceutical Packaging Association organized a seminar on hollow capsule standards
Time of Update: 2022-08-15
The association will guide member units to actively participate in standardization activities at home and abroad, cooperate with the work of Zhejiang Institute, carry out relevant special research work, and jointly promote the high-quality development of the hollow capsule industry .
-
Seeing "her power": within one day, many pharmaceutical companies announced new female executives!
Time of Update: 2022-08-15
Among them, on July 28, the company announced that its board of directors received written resignation reports from director and general manager Wang Hongxin and deputy general managers Yuan Yingsheng and Chen Jing According to the company's previous announcement, the senior executives of China Pharmaceutical changed frequently during the year.
-
The threat of patent expiration goes deep!
Time of Update: 2022-08-15
. In conclusion, mergers and acquisitions or partnering with smaller biopharmaceutical companies (such as forming alliances) can help pharma companies significantly close the innovation gap they may face in the coming years .
-
11 pharmaceutical companies have been surveyed by more than 20 institutions, and nearly half of them have disclosed their performance results.
Time of Update: 2022-08-15
. Among them, Kaili Medical announced on July 7 that it is expected to achieve a net profit of 160 million to 200 million yuan attributable to shareholders of listed companies in the first half of 2022, an increase of 46.
-
Why do a large number of pharmaceutical companies "marriage" and "break up" at the same time?
Time of Update: 2022-08-15
In addition, Sanofi also announced at the beginning of the year that it would terminate the cooperation transaction with Sangamo, abandon personalized cell therapy, and shift the research and development focus to allogeneic universal genomic medicine methods .
-
GSK's single-tablet, dual-drug HIV drug Dovito® approved for expanded indications
Time of Update: 2022-08-15
Agency approval as a complete regimen for the treatment of HIV-1-infected adults and adolescents over 12 years of age who have achieved virological suppression On May 11, GlaxoSmithKline (GSK) announced that its innovative single-tablet dual-drug HIV treatment program, Dovito (generic name: lamivudine and dolutegravir), has been officially approved by the National Medical Products Administration of China for its expanded indications.
-
The medical insurance negotiation declaration is in full swing!
Time of Update: 2022-08-15
0 1 Reasonable competition and standard price Encourage horizontal comparison of products As in previous years, this year's medical insurance negotiation work is still divided into five stages: preparation, declaration, expert review, negotiation/bidding, and announcement of results .
-
Is the domestic oral new crown drug Azvudine safe?
Time of Update: 2022-08-15
Cen Xiaobo said, "To talk about the safety of a drug from a professional point of view, it is necessary to comprehensively analyze factors such as drug (safe) dose/administration route and clinical human drug exposure/drug concentration in toxicity tests.
-
How many "dark horses" can domestic ADCs run?
Time of Update: 2022-08-15
Research and development progress of SHR-A1811, source: Hengrui Medicine 2021 Annual Report Lepu Bio has acquired a number of ADC drugs and ADC R&D platforms that are still in the early stage due to the acquisition of the controlling stake in Shanghai Meiya, and has become a leading pharmaceutical company in the domestic ADC track .
-
A batch of medical device registration certificates have been cancelled!
Time of Update: 2022-08-15
On April 21, the Henan Provincial Drug Administration issued an announcement (No. 46, 2022) on the cancellation of the registration certificate of medical device products, stating that in accordance with the "Regulations on the Supervision and Administration of Medical Devices", according to the application of the enterprise, Yuan (Henan) is now cancelled.
-
In the first half of 2022, 12 medicines for children were approved!
Time of Update: 2022-08-15
Table 2 New medicines for children approved in China in the first half of 2022 Source: Collation of public information Among the 12 new drugs approved in the first half of 2022, 7 are new dosage forms/specifications; they are mainly developed for children with poor compliance and differences in dosage from adults .
-
Priority introduction and price exposure, the new crown neutralizing antibody welcomes the highlight moment?
Time of Update: 2022-08-15
3 New crown neutralizing antibody research and development is hot More than 30 domestic enterprises are deployed According to incomplete statistics, there are 7 types of COVID-19 neutralizing antibody therapies on the market globally, namely Casirizumab + Idezumab from Roche and Regeneron, and Atelizumab + Banivirumab from Eli Lilly.
-
Another pharmaceutical company has been intensively investigated by the organization!
Time of Update: 2022-08-15
. Among the blockbuster products, HP518, a new drug for the treatment of drug-resistant prostate cancer, was independently developed and successfully promoted to enter Phase I clinical trials in Australia, and achieved the first patient administration (FIH).
-
The seventh batch of national arrows is on the line, in-depth analysis of the competition pattern of pharmaceutical companies
Time of Update: 2022-08-15
The rules are basically mature and steadily advancing After three years and six batches of practice in the national centralized procurement, the rules are constantly improving, and a basic institutional framework for normalization and institutionalization has been formed, including three levels: First, price discovery is carried out through the national centralized procurement bidding process, and the price is bottomed out on the premise of ensuring the reasonable profits of the enterprise .
